This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
MIER2 Monoclonal Antibody (OTI3G7)
catalog :
MA5-25858
quantity :
100 uL
price :
US 514.00
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
OTI3G7
The same clone is also sold as:
The same clone is also sold as:
- OriGene: TA504260S, TA504260, TA504260AM, CF504260, TA504260BM
- Novus Biologicals: NBP2-72683, NBP2-01748
reactivity :
human
application :
western blot, immunohistochemistry, immunohistochemistry - paraffin section
product information
Product Type :
Antibody
Product Name :
MIER2 Monoclonal Antibody (OTI3G7)
Catalog # :
MA5-25858
Quantity :
100 uL
Price :
US 514.00
Clonality :
Monoclonal
Purity :
Affinity Chromatography
Host :
Mouse
Reactivity :
Human
Applications :
Immunohistochemistry (Paraffin): 1:150, Western Blot: 1:2,000
Species :
Human
Clone :
OTI3G7
Isotype :
IgG1
Storage :
-20 C, Avoid Freeze/Thaw Cycles
Description :
Transcriptional repressor.
Immunogen :
Human recombinant protein fragment corresponding to amino acids 1-296 of MIER2 produced in E.coli
Format :
Liquid
Applications w/Dilutions :
Immunohistochemistry (Paraffin): 1:150, Western Blot: 1:2,000
Aliases :
2700087H15Rik; KIAA1193; mesoderm induction early response 1, family member 2; mesoderm induction early response protein 2; MIER family member 2; MIER2; Mi-er2; mKIAA1193; RGD1307278
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments